Is MGM-16 Legal in Rhode Island? (2026)

Instrument

statute

Source

https://webserver.rilegislature.gov/Statutes/TITLE21/21-28/21-28-2.01.htm

Retrieved

2026-11-02

Fingerprint

56882115b0c50d2b

(a) (1)

The director of health shall control all substances enumerated in § 21-28-2.08 or may by motion or on the petition of any interested party pursuant to the procedures      of chapter 35 of title 42, the Administrative Procedures Act, add, reschedule, or      delete a substance as a controlled substance. In making this determination, the director      of health shall consider, but not be limited to the following:
(i)

( Its actual or relative potential for abuse;
(ii)

Scientific evidence of its pharmacological effect if known;
(iii)

State of current scientific knowledge regarding the substance;
(iv)

Its history and current pattern of abuse;
(v)

The scope, duration, and significance of abuse;
(vi)

What, if any, risk there is to the public health;
(vii)

Its psychic or physiological dependence liability;
(viii)

Whether the substance is an immediate precursor of a substance already controlled      under this chapter.
(2)

After considering the factors in subdivision (1) of this section the director of health      shall make findings with respect to these factors and shall issue an order controlling      the substance if it is found that the substance has potential for abuse.
(b)

If the director of health designates a substance as an immediate precursor, substances      which are precursors of the controlled precursor shall not be subject to control solely      because they are precursors of the controlled precursor.
(c)

If any substance is designated, rescheduled, or deleted as a controlled substance      under federal law and notice of that action is given to the director of health, he      or she shall similarly control the substance under this chapter after the expiration      of sixty (60) days from publication in the federal register of a final order designating      a substance as a controlled substance or rescheduling or deleting a substance, unless      within that sixty (60) day period, the director of health objects to inclusion, rescheduling,      or deletion. In that case, the director of health shall publish the reasons for objection      and afford all interested parties an opportunity to be heard. At the conclusion of      the hearing, the director of health shall publish his or her decision, which shall      be final unless altered by statute. The director of health shall publish and file      his or her decision with the secretary of state. Upon publication of objection to      inclusion, rescheduling, or deletion under this chapter by the director of health,      control under this chapter is stayed until the director of health publishes his or      her decision.

Instrument

Rhode Island Kratom Act: definitions (kratom product; synthesized material); kratom and kratom product limitations

Source

https://webserver.rilegislature.gov/Statutes/TITLE21/21-28.12/21-28.12-3.htm

Retrieved

2026-11-08

Fingerprint

dd36cfafe87580c0

"Kratom product" means a product containing any part or extract of the leaf of the
plant mitragyna speciosa or an extract thereof including concentrated forms of kratom
and products composed of kratom and other ingredients.

“Synthesized material” means:

(i)
An alkaloid or alkaloid derivative that has been created by chemical synthesis or
biosynthetic means (including, but not limited to, fermentation, recombinant techniques,
yeast derived, enzymatic techniques), rather than traditional food preparation techniques,
such as heating or extracting that synthetically alters the composition of any kratom
alkaloid or constituent; or 

(ii)
An alkaloid or alkaloid derivative contained in kratom that has been exposed to chemicals
or processes that would confer a structural change in the alkaloids, resulting in
material that has been chemically altered.

(a)
A person shall not prepare, distribute, sell, possess, or advertise any of the following:

(1)
A kratom product that is a conventional food or beverage or labeled as a conventional
food or beverage product.

(2)
A kratom product that contains any substance that is poisonous, harmful, or injurious
to health.

(3)
A kratom product that contains a substance other than a non-psychoactive substance
necessary for the preparation, processing, or manufacturing
of said product.

(4)
A kratom extract that contains levels of residual solvents higher than is allowed
in the U.S. Pharmacopeia 467.

(5)
A kratom product containing any synthetic alkaloids including synthetic mitragynine,
synthetic 7-hydroxymitragynine, or any other synthetically derived compounds of the
kratom plant.

(6)
A kratom product that contains a heavy metal that exceeds any of the following limits
in parts per million:

(i)
Arsenic <2

(ii)
Cadmium <0.82

(iii)
Lead <1.2

(iv)
Mercury <0.4

(7)
A kratom product in any form that is combustible or intended to be used for vaporization,
aerosolization, or injection.

(8)
A kratom product in any form that mimics a candy product or is manufactured, packaged,
or advertised in a way that can be reasonably considered
to appeal to individuals under twenty-one (21) years.

(9)
A kratom product not contained in child-resistant packaging that meets the standards
set forth in 16 C.F.R 1700.15(b) when tested in accordance with 16 C.F.R 1700.20. All persons holding valid licenses pursuant to § 21-28.12 shall ensure that kratom
and/or any kratom product sold by the licensee and intended for human consumption
shall meet requirements related to child-resistant packaging.

(10)
A kratom product that contains a concentration ratio that is:

(i)
Greater than 150 mg of mitragynine per serving;

(ii)
Greater than 0.5 mg 7-hydroxymitragynine per gram; or

(iii)
Greater than 1 mg 7-hydroxymitragynine per serving.

(11)
A kratom product that contains more than one percent of 7-hydroxymitragynine by percentage
of total kratom alkaloids.

(12)
Kratom or a kratom product that does not provide clearly visible labeling including,
but not limited to:

(i)
A recommendation to consult a healthcare professional prior to use;

(ii)
A statement that kratom may be habit forming;

(iii)
A statement that kratom is not safe for use while pregnant or breastfeeding;

(iv)
A warning that the product may result in dangerous medication interactions.

(v)
The following statement: “These statements have not been evaluated by the United States
Food and Drug Administration. This product is not
intended to diagnose, treat, cure, or prevent any disease.”;

(vi)
The net quantity of contents declared in numerical count (e.g., thirty (30) capsules),
or in volume or weight in United States Customary
System terms;

(A)
The amount of mitragynine and/or 7-hydroxymitragynine contained in a serving in said
kratom product;

(B)
A recommended amount of the kratom product per serving; and

(C)
A recommended number of servings that can be safely consumed in a twenty-four-hour
(24) period.

(vii)
The total amount of mitragynine and 7-hydroxymitragynine contained in the kratom
product;

(viii)
A statement that this product should be stored safely and out of the reach of children;

(ix)
The name, physical non-post office box address of the manufacturer.

(b)
Kratom and kratom products sold at retail must be sold by a licensed retailer and
must be obtained from a licensed manufacturer, importer, or distributor.

(c)
All kratom and kratom products that do not comply with subsection (a) of this section
shall be deemed contraband.

Instrument

Rhode Island Kratom Act: kratom and kratom product limitations

Source

https://webserver.rilegislature.gov/Statutes/TITLE21/21-28.12/21-28.12-3.htm

Retrieved

2026-10-29

Fingerprint

aceaeac3dc1b05d1

A person shall not prepare, distribute, sell, possess,  or advertise any of the following:

(1)
 A kratom product that is a conventional food or  beverage or labeled as a conventional
            food or beverage product.

(2)
 A kratom product that contains any substance  that is poisonous, harmful, or injurious
            to health.

(3)
 A kratom product that contains a substance other  than a non-psychoactive substance
            necessary for the preparation,                          processing, or manufacturing
            of said product.

(4)
 A kratom extract that contains levels of  residual solvents higher than is allowed
            in the U.S. Pharmacopeia 467.

(5)
 A kratom product containing any synthetic alkaloids including synthetic mitragynine,
            synthetic 7-hydroxymitragynine, or any other synthetically derived compounds of the
            kratom plant.

(6)
 A kratom product that contains a heavy metal that exceeds any of the following limits
            in parts per million:

(i)
 Arsenic <2

(ii)
 Cadmium <0.82

(iii)
 Lead  <1.2

(iv)
 Mercury  <0.4

(7)
 A kratom product in any form that is combustible or intended to be used for vaporization,
            aerosolization, or injection.

(8)
 A kratom product in any form that mimics a candy product or is manufactured, packaged,
            or advertised in a way that can be                          reasonably considered
            to appeal to individuals under twenty-one (21) years.

(9)
 A kratom product not contained in  child-resistant packaging that meets the standards
            set forth in 16 C.F.R 1700.15(b) when tested in accordance with 16 C.F.R 1700.20. All persons holding valid licenses pursuant to § 21-28.12 shall ensure that kratom
            and/or any kratom product sold by the licensee and intended for human consumption
            shall meet requirements related to child-resistant                          packaging.

(10)
 A kratom product that contains a concentration  ratio that is:

(i)
 Greater than 150 mg of mitragynine per  serving;

(ii)
 Greater than 0.5 mg 7-hydroxymitragynine  per gram; or

(iii)
 Greater than 1 mg 7-hydroxymitragynine  per serving.

(11)
 A kratom product that contains more than one  percent of 7-hydroxymitragynine by percentage
            of total kratom alkaloids.

(12)
 Kratom or a kratom product that does not provide  clearly visible labeling including,
            but not limited to:

(i)
 A recommendation to consult a healthcare professional prior to use;

(ii)
 A statement that kratom may be habit  forming;

(iii)
 A statement that kratom is not safe for  use while pregnant or breastfeeding;

(iv)
 A warning that the product may result in dangerous medication interactions.

(v)
 The following statement: “These statements have not been evaluated by the United States
            Food and                                  Drug Administration. This product is not
            intended to diagnose, treat, cure, or prevent any disease.”;

(vi)
 The net quantity of contents declared in numerical count (e.g., thirty (30) capsules),
            or in volume or                                  weight in United States Customary
            System terms;

(A)
 The amount of mitragynine and/or  7-hydroxymitragynine contained in a serving in said
            kratom product;

(B)
 A recommended amount of the  kratom product per serving; and

(C)
 A recommended number of servings  that can be safely consumed in a twenty-four-hour
            (24) period.

(vii)
 The total amount of mitragynine and  7-hydroxymitragynine contained in the kratom
            product;

(viii)
 A statement that this product should be  stored safely and out of the reach of children;

(ix)
 The name, physical non-post office box  address of the manufacturer.

(b)
 Kratom and kratom products sold at retail must be sold  by a licensed retailer and
            must be obtained from a licensed manufacturer,                  importer, or distributor.

(c)
 All kratom and kratom products that do not comply with  subsection (a) of this section
            shall be deemed contraband.

Instrument

RI Kratom Act - age 21, 1% total-alkaloid + 1 mg/serving + 0.5 mg/g 7-OH caps, synthetic ban

Source

https://webserver.rilegislature.gov/Statutes/TITLE21/21-28.12/21-28.12-3.htm

Retrieved

2026-07-07

Fingerprint

4460c490f2ad961e

21-28.12-3. (a) A person shall not prepare, distribute, sell, possess, or advertise: ... (5) A kratom product containing any synthetic alkaloids including synthetic mitragynine, synthetic 7-hydroxymitragynine, or any other synthetically derived compounds of the kratom plant. ... (7) combustible or intended for vaporization, aerosolization, or injection. (8) mimics a candy product / appeals to under-21. (9) not child-resistant packaging. (10) A kratom product that contains a concentration ratio that is: (i) Greater than 150 mg of mitragynine per serving; (ii) Greater than 0.5 mg 7-hydroxymitragynine per gram; or (iii) Greater than 1 mg 7-hydroxymitragynine per serving. (11) A kratom product that contains more than one percent of 7-hydroxymitragynine by percentage of total kratom alkaloids. (12) [labeling]. (c) noncompliant kratom deemed contraband.
21-28.12-4. (a) No person shall distribute, sell, transfer, or advertise a kratom product to a person under 21 years. (b) behind the sales counter. (d) valid photo ID required.